Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has released its Q3 report for 2025, indicating that the company achieved a revenue of 853 million yuan in the first three quarters, marking a year-on-year increase of 16.86%. The net profit attributable to shareholders was 345 million yuan, reflecting a year-on-year growth of 26.67%. The net profit after deducting non-recurring gains and losses attributable to shareholders reached 340 million yuan, up 28.92% year-on-year. The basic earnings per share stood at 0.6587 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments